TroFuse-01ANCT07908524
MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Secondary (2)
Arms and interventions
Participants will receive docetaxel every 3 weeks by intravenous (IV) infusion. Participants will also receive either prednisone or prednisolone daily (or per approved product label).
Participants will receive sac-TMT monotherapy every 2 weeks (q2w) by IV infusion.
Participants will receive sac-TMT monotherapy q2w by IV infusion.
Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of opevesostat twice daily until any of the criterion for discontinuation are met. Participants receiving opevesostat will receive fludrocortisone and dexamethasone daily.
Participants will receive sac-TMT q2w by IV infusion in combination with oral administration of an androgen receptor pathway inhibitor (ARPI), either abiraterone acetate daily or enzalutamide daily until any of the criterion for discontinuation are met. Participants receiving abiraterone acetate will also receive either prednisone or prednisolone daily (or per approved product label).
Biologicals: Sacituzumab tirumotecan
Drugs: Rescue medication, Docetaxel, Prednisone, Opevesostat, Abiraterone acetate, Enzalutamide, Prednisolone, Fludrocortisone, Dexamethasone